Synvista Therapeutics, Inc. (SYNI) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SYNI representa a Synvista Therapeutics, Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 46/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Synvista Therapeutics, Inc. (SYNI) Resumen de Asistencia Médica y Tuberías
Synvista Therapeutics, Inc. is a biopharmaceutical company specializing in treatments for diabetic patients at risk of cardiovascular disease. Their pipeline features ALT-2074, a glutathione peroxidase mimetic, and Alagebrium chloride, an Advanced Glycation End-product Crosslink Breaker, both currently in Phase II clinical trials, positioning them in the competitive pharmaceuticals market.
Tesis de Inversión
Synvista Therapeutics, Inc. presents a high-risk, high-reward investment profile due to its focus on developing treatments for diabetic patients at risk of cardiovascular disease. The company's pipeline, featuring ALT-2074 and Alagebrium chloride in Phase II trials, represents potential value drivers if clinical trials are successful. However, the company's small market capitalization and OTC listing introduce significant liquidity and regulatory risks. Successful completion of Phase II trials and subsequent partnerships or acquisitions could drive significant returns. The company's beta of -5.15 suggests an inverse correlation with the market, which may offer diversification benefits in certain market conditions.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Synvista Therapeutics focuses on developing diagnostic tests and drugs for diabetic patients at high risk for cardiovascular disease.
- The company's lead product candidates, ALT-2074 and Alagebrium chloride, are both in Phase II clinical trials.
- ALT-2074 is a glutathione peroxidase mimetic for the treatment of diabetic patients with Hp2-2.
- Alagebrium chloride is an Advanced Glycation End-product Crosslink Breaker for the treatment of diastolic heart failure and diabetic nephropathy.
- Synvista Therapeutics trades on the OTC market, indicating higher risk and lower liquidity compared to major exchanges.
Competidores y Pares
Fortalezas
- Focus on a specific niche within diabetes care (cardiovascular complications).
- Proprietary drug candidates in Phase II clinical trials.
- Potential for high returns if clinical trials are successful.
Debilidades
- Small market capitalization and limited financial resources.
- Reliance on a small number of drug candidates.
- OTC listing indicates higher risk and lower liquidity.
Catalizadores
- Upcoming: Release of Phase II clinical trial results for ALT-2074.
- Upcoming: Announcement of potential partnerships with larger pharmaceutical companies.
- Upcoming: Progress on the development of a diagnostic test for cardiovascular risk in diabetic patients.
Riesgos
- Potential: Failure of clinical trials for ALT-2074 or Alagebrium chloride.
- Ongoing: Competition from larger pharmaceutical companies with more resources.
- Potential: Regulatory hurdles and delays in FDA approval.
- Ongoing: Limited financial resources and reliance on external funding.
- Ongoing: Risks associated with trading on the OTC market, including low liquidity and price volatility.
Oportunidades de crecimiento
- Successful completion of Phase II clinical trials for ALT-2074: Positive results from the Phase II trials could lead to increased investor confidence and potential partnerships with larger pharmaceutical companies. The market for treatments targeting diabetic patients with the Hp2-2 genotype is significant, offering a substantial revenue opportunity if the drug proves effective. The timeline for Phase III trials and potential FDA approval could extend several years, but successful Phase II data would be a major catalyst.
- Advancement of Alagebrium chloride through clinical trials: Alagebrium chloride targets diastolic heart failure and diabetic nephropathy, both significant complications of diabetes. Positive clinical trial results could open up a large market opportunity. The development timeline is lengthy, but successful trials would significantly increase the company's value. The market for heart failure and diabetic nephropathy treatments is substantial and growing.
- Development and commercialization of a diagnostic test for cardiovascular risk in diabetic patients: A successful diagnostic test could provide a recurring revenue stream and differentiate Synvista from competitors. The market for diagnostic tests in diabetes is expanding, driven by the need for early detection and prevention of complications. The timeline for development and commercialization depends on regulatory approval and market adoption.
- Strategic partnerships with larger pharmaceutical companies: Collaborations with established pharmaceutical companies could provide Synvista with funding, expertise, and access to larger markets. Partnerships could accelerate the development and commercialization of Synvista's products. The pharmaceutical industry is characterized by collaborations between smaller biotech firms and larger companies, offering potential opportunities for Synvista.
- Expansion into new therapeutic areas within diabetes: Synvista could leverage its expertise in diabetes to develop treatments for other complications, such as retinopathy and neuropathy. Expanding the product pipeline would diversify the company's revenue streams and reduce its reliance on a single product. The market for diabetes treatments is broad and offers numerous opportunities for innovation.
Oportunidades
- Successful completion of Phase II trials could lead to partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas within diabetes.
- Development and commercialization of a diagnostic test for cardiovascular risk in diabetic patients.
Amenazas
- Failure of clinical trials.
- Competition from larger pharmaceutical companies with more resources.
- Regulatory hurdles and delays in FDA approval.
Ventajas competitivas
- Proprietary drug candidates with patent protection.
- Specialized focus on cardiovascular complications of diabetes.
- Clinical trial data demonstrating safety and efficacy.
Acerca de SYNI
Synvista Therapeutics, Inc., formerly known as Alteon, Inc., was founded in 1986 and is headquartered in Parsippany, New Jersey. The company operates as a product-based biopharmaceutical entity, focusing on the development of diagnostic tests and drugs aimed at identifying and treating diabetic patients who are at high risk of developing cardiovascular disease. Synvista's product pipeline includes ALT-2074, a glutathione peroxidase mimetic currently in Phase II clinical trials for treating diabetic patients with the Hp2-2 genotype. Additionally, they are developing Alagebrium chloride, also in Phase II clinical trials, targeting diastolic heart failure and diabetic nephropathy. The company is also working on a diagnostic test designed to identify and treat diabetic patients at risk of cardiovascular disease. Synvista's strategic focus on diabetes-related cardiovascular complications positions it within a niche segment of the pharmaceutical industry, addressing a significant unmet medical need.
Qué hacen
- Develop diagnostic tests for diabetic patients at high risk for cardiovascular disease.
- Develop drugs to treat diabetic patients at high risk for cardiovascular disease.
- Focus on glutathione peroxidase mimetics for treating diabetic patients with Hp2-2.
- Develop Advanced Glycation End-product Crosslink Breakers for treating diastolic heart failure and diabetic nephropathy.
- Conduct Phase II clinical trials for ALT-2074.
- Conduct Phase II clinical trials for Alagebrium chloride.
Modelo de Negocio
- Develops and patents novel therapeutic compounds.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from the FDA.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
Contexto de la Industria
Synvista Therapeutics operates within the medical pharmaceutical industry, a sector characterized by intense research and development, stringent regulatory oversight, and high capital requirements. The market for diabetes-related treatments is substantial, driven by the increasing prevalence of diabetes globally. Competition includes major pharmaceutical companies and smaller biotech firms focusing on innovative therapies. Synvista's focus on cardiovascular complications of diabetes positions it within a specialized niche, potentially offering a competitive advantage if its clinical trials are successful. The industry is also influenced by trends in personalized medicine and diagnostic testing, aligning with Synvista's development of a diagnostic test for cardiovascular risk in diabetic patients.
Clientes Clave
- Diabetic patients at high risk for cardiovascular disease.
- Hospitals and clinics specializing in diabetes care.
- Pharmaceutical companies seeking to expand their diabetes product portfolios.
Finanzas
Gráfico e información
Precio de la acción de Synvista Therapeutics, Inc. (SYNI): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para SYNI.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para SYNI.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para SYNI.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de SYNI en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Información del mercado OTC de SYNI
The OTC Other tier represents the lowest tier of the OTC market, indicating that Synvista Therapeutics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a significantly higher risk compared to companies listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Higher risk of price manipulation.
- Potential for delisting or suspension of trading.
- Lack of regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if available).
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Research the company's industry and market trends.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Company has been in operation since 1986.
- Focus on developing treatments for a specific medical need (diabetes-related cardiovascular complications).
- Drug candidates are in Phase II clinical trials.
Lo Que los Inversores Preguntan Sobre Synvista Therapeutics, Inc. (SYNI)
¿Cuáles son los factores clave para evaluar SYNI?
Synvista Therapeutics, Inc. (SYNI) actualmente tiene una puntuación IA de 46/100, indicando puntuación baja. Fortaleza clave: Focus on a specific niche within diabetes care (cardiovascular complications).. Riesgo principal a monitorear: Potential: Failure of clinical trials for ALT-2074 or Alagebrium chloride.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de SYNI?
SYNI actualmente puntúa 46/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de SYNI?
Los precios de SYNI se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre SYNI?
La cobertura de analistas para SYNI incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en SYNI?
Las categorías de riesgo para SYNI incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Failure of clinical trials for ALT-2074 or Alagebrium chloride.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de SYNI?
La relación P/E para SYNI compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está SYNI sobrevalorada o infravalorada?
Determinar si Synvista Therapeutics, Inc. (SYNI) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de SYNI?
Synvista Therapeutics, Inc. (SYNI) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available sources and may be incomplete or outdated.
- OTC market data may be limited and less reliable than data from major exchanges.
- AI analysis pending for SYNI.